RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.3

Change

-0.28 (-2.42)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-13 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.06 (-0.14%)

USD 0.89B
SOXS Direxion Daily Semiconductor B..

+0.14 (+0.65%)

USD 0.72B
PSQ ProShares Short QQQ

+0.14 (+0.37%)

USD 0.51B
SPXU ProShares UltraPro Short S&P50..

-0.10 (-0.43%)

USD 0.50B
SDOW ProShares UltraPro Short Dow30

-1.32 (-2.49%)

USD 0.26B
YANG Direxion Daily FTSE China Bear..

-0.77 (-0.93%)

USD 0.18B
FNGD MicroSectors FANG+ Index -3X I..

+0.36 (+2.57%)

USD 0.17B
SPDN Direxion Daily S&P 500® Bear ..

-0.02 (-0.18%)

USD 0.14B
RWM ProShares Short Russell2000

-0.03 (-0.16%)

USD 0.14B
DOG ProShares Short Dow30

-0.22 (-0.82%)

USD 0.13B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.04% 11% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.04% 11% F 11% F
Trailing 12 Months  
Capital Gain 0.27% 98% N/A 43% F
Dividend Return 3.70% 74% C 53% F
Total Return 3.97% 98% N/A 40% F
Trailing 5 Years  
Capital Gain -65.65% 69% C- 7% C-
Dividend Return 2.76% 64% D 7% C-
Total Return -62.89% 69% C- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 63.00% 40% F 95% A
Dividend Return 64.21% 40% F 95% A
Total Return 1.21% 58% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 433.81% 62% D 3% F
Risk Adjusted Return 14.80% 45% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.